With over 20 million Tropis ID injections supplied globally, PharmaJet is making important contributions to the Global Polio ...

GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet ®, a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced they received an ...

GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet ®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System (NFIS) will be used in a clinical trial to ...

PharmaJet’s Needle-free intradermal (ID) injection device ("Tropis ® ID") will be evaluated as delivery system for the tuberculin skin test (TST) in a clinical study conducted by REDE-TB. The study ...

PharmaJet has struck an agreement covering the use of its Tropis needle-free injection system in Nigeria, positioning vaccinators to deploy the technology in a project intended to tackle a poliovirus ...

PharmaJet® to Highlight the Benefits of Intradermal Needle-free Delivery and Expansion into the Self-Injection Pen Market at Upcoming PODD Conference PharmaJet will deliver two presentations on ...

PharmaJet ®, a company focused on improving the performance and outcomes of injectables through needle-free injection technology, announced that its partner, Brazilian Tuberculosis Research Network ...

The MarketWatch News Department was not involved in the creation of this content. -- PharmaJet's Needle-free intradermal (ID) injection device ("Tropis(R) ID") will be evaluated as delivery system for ...